Sarfez Pharmaceuticals, Inc.   Report issue

For profit Phase 1
Founded: Vienna VA United States (2006)
Status: No NME R&D (2006)

Organization Overview

First Clinical Trial
2017
NCT03214874
First Marketed Drug
2021
torsemide (demadex)
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Sarfez Pharmaceuticals, Inc. | SARFEZ PHARMACEUTICALS INC